已收录 268921 条政策
 政策提纲
  • 暂无提纲
Measurement of free-circulating cis-dichlorodiammineplatinum(II) in plasma.
[摘要] Dichlorodiammineplatinum(II) is an anti-neoplastic agent that is currently undergoing clinical evaluation. We describe an analytical method for monitoring the free drug (or its breakdown products) in plasma. The method is able to distinguish between free and protein-bound drug. Plasma samples are deproteinized by centrifugal ultrafiltration. The platinum in the ultrafiltrate is converted to a cationic species by reaction with ethylenediamine and then collected on paper impregnated with cation-exchange resin. This process concentrates the samples, increases the stability of the platinum compounds (by removing the compound from solution), and places the sample in a uniform matrix of minimum thickness, which maximizes detection capabilities. Platinum was measured directly on the ion-exchange disks by X-ray fluorescence. The detection limit for free drug is 240 microgram/liter of plasma at the 3s level and fluorescence intensity is linearly related to drug concentration in the range from 570 to 5700 microgram/liter.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 过敏症与临床免疫学
[关键词]  [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文